SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) July 22, 1997
-----------------------
IMATRON INC.
- ------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
- ------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-12405 94-2880078
- ------------------------------ ----------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
389 Oyster Point Boulevard, South San Francisco, CA 94080
- ------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(415) 583-9964
- ------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
- -----------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. Development Agreement with TeraRecon Inc.
On July 22, 1997, the Company and TeraRecon Inc. entered into a development
agreement whereby TeraRecon will provide Imatron with a real-time image
reconstruction system for use in conjunction with Imatron's Ultrafast CT
scanner. Upon completion and when delivered, the RTR-2000 system will be
exclusive to Imatron's Ultrafast CT scanner and will expand its current
applications to include new three- dimensional, CT flurography or real-time
viewing of computerized tomography (CT) images.
In consideration for the successful development and delivery of
specifically mandated RTR-2000 systems, the Company has agreed to issue an
aggregate of 6 million warrants to purchase the Company's Common Stock at $4.50
per share. The warrants will be issued in installments based on TeraRecon
achieving certain milestones in connection with the development of image
reconstruction systems. In addition, TeraRecon has agreed to pay the Company an
aggregate of $2 million for 4 million of the warrants and to make royalty
payments to Imatron equal to 3% of Net Sales of certain RTR-2000 systems sold to
third parties. Upon successful completion of the prototype development program,
the parties intend to enter into a manufacture and sale agreement whereby
Imatron will have the exclusive right to sell or lease the RTR-2000 systems to
purchasers of Imatron's Ultrafast CT scanner. TeraRecon will retain the right to
sell, lease or license the RTR-2000 system to other medical imaging systems
customers provided that such systems do not include any Imatron technology.
Neither party to the agreement has granted a license of any of its technology to
the other. The term of the agreement continues until the final development
milestone is completed and accepted and the RTR-2000 system is accepted by
Imatron and the Imatron warrants are delivered.
ITEM 7. Exhibits.
7.1 TeraRecon Systems Development and Porting Agreement between Imatron
Inc. and TeraRecon Inc. dated as of July 22, 1997. 7.2 Press release issued in
connection with the signing of the TeraRecon Systems Development and Porting
Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMATRON INC.
----------------------------------------
Date: July 31, 1997 By:/s/ Gary H. Brooks
----------------------------------------
Gary H. Brooks
Its:Vice President, Finance and
Administration, Chief Financial
Officer and Secretary
TERARECON SYSTEMS DEVELOPMENT
AND PORTING AGREEMENT
THIS DEVELOPMENT AND PORTING AGREEMENT (the "Agreement") is made as of this
___ day of _____________, 1997 (the "Effective Date") by and between TERARECON
INC. ("TeraRecon"), a Delaware corporation, and IMATRON INC. ("Imatron"), a New
Jersey corporation.
WHEREAS, TeraRecon has developed a proprietary image reconstruction system;
WHEREAS, Imatron has developed certain image reconstructions algorithms for
use in the reconstruction of Ultrafast CT(TM) images for medical scanning
applications;
WHEREAS, the parties desire TeraRecon to develop certain stand-alone image
reconstruction systems incorporating the Imatron algorithms into the TeraRecon
image reconstruction system to be sold by Imatron and used in conjunction with
certain Imatron scanners, as more fully described herein;
WHEREAS, Imatron has agreed to issue warrants to TeraRecon to acquire
shares of Imatron's Common Stock upon the completion of certain milestones in
connection with the development of such image reconstruction systems; and
WHEREAS, TeraRecon desires to develop such image reconstruction systems
upon the terms and conditions set forth herein.
NOW, THEREFORE, the parties hereby agree as follows:
1. Definitions.
As used herein, the following terms shall have the following meanings:
1.1. "Confidential Information" means any information, technical data, or
know-how, including, but not limited to, a party's research, products, hardware,
software, services, development, inventions, processes, designs, drawings,
engineering, marketing, finances, or such other information that is or has been
made available to the party receiving the information (the "Receiving Party") by
the party disclosing the information (the "Disclosing Party") either directly or
indirectly in writing, orally or by drawings or inspection of parts or
equipment. Notwithstanding anything to the contrary in this Agreement, neither
party shall have any obligation under this Agreement with respect to
Confidential Information unless: (A) if the Confidential Information is in
writing or other tangible form (i.e., electronic), it is clearly marked as
proprietary and confidential when furnished to the Receiving Party: or, (b) if
the Confidential Information is not in tangible form, it is identified orally
and specifically as proprietary and confidential at the time of disclosure and
is summarized in a writing so marked and delivered to the Receiving Party within
thirty (30) days after such disclosure, in which case the Confidential
Information contained in such summary (not information contained solely in the
non-tangible disclosure) shall be subject to the restrictions herein; provided,
however, that each party shall have thirty (30) days from the date hereof to
summarize all information previously disclosed to the Receiving Party and not
marked confidential, and all such information shall be deemed Confidential
Information. Neither party has any obligation to disclose any particular
information to the other under this Agreement. Confidential Information shall
not include any data or information which (i) was in the public domain at the
time it was disclosed or falls within the public domain, except through the
fault of a Receiving Party; (ii) was known to the Receiving Party at the time of
disclosure, which knowledge the Receiving Party shall have the burden of
establishing by clear and convincing evidence; (iii) was disclosed after written
approval of the Disclosing Party; (iv) becomes known to the Receiving Party from
a source other than the Disclosing Party without breach of this Agreement by the
Receiving Party; or (v) was independently developed by the Receiving Party
without the benefit of Confidential Information received from the Disclosing
Party, which independent development the Receiving Party shall have the burden
of establishing by clear and convincing evidence.
1.2. "Development Program" means the collaborative development program
undertaken by the parties pursuant to this Agreement, all as more fully set
forth in Appendix A. 1.3. "Error" means any material failure by a Prototype I or
Prototype II which causes such Prototype I or Prototype II not to operate in
conformance with the Specifications.
1.4. "Fair Market Value" means the average of the closing or last reported
sale prices on the NASDAQ National Market over the 5-day period ending five days
prior to Acceptance as defined in Section 3.2.
1.5. "Hardware Updates" shall mean any error corrections or other
modifications to the hardware, prepared by or on behalf of TeraRecon that may
enhance performance of the hardware but do not add significant new, different or
enhanced functions or functionality to the hardware.
1.6. "Hardware Upgrades" shall mean a new generation of the hardware,
prepared by or on behalf of TeraRecon, that adds significant new or enhanced
functions or functionality to the hardware, or is meant to significantly change
or enhance the performance of the hardware.
1.7. "Imaging Enhancements" shall mean any error corrections or other
modifications to the software, prepared by or on behalf of TeraRecon, that may
enhance performance of the software. In the event that TeraRecon undertakes the
development of significant new or enhanced functions or functionality to the
software for medical imaging interventional radiology applications, which do not
require Hardware Upgrades, then such new or enhanced functions or functionality
shall be included in "Imaging Enhancements."
1.8. "Imatron Technology" means the proprietary Imatron reconstruction
algorithms, and all Intellectual Property Rights included therein necessary to
create the TeraRecon Systems as identified on Appendix B.
1.9. "Intellectual Property Rights" means copyrights, patents, trade
secrets and trademarks, whether or not registered, filed, applied for or the
like, and all related rights.
1.10. "Net Sales" means the gross sales price received by TeraRecon
attributable to TeraRecon's sale, lease or license of the RTR-2000 TeraRecon
System in connection with medical CT scanning applications to parties using CT
scanner applications other than Imatron or affiliates of TeraRecon less shipping
expenses, discounts, returns and taxes.
1.11. "Non-Imaging Enhancements" shall mean a major new release of the
software, prepared by or on behalf of TeraRecon, that adds significant new or
enhanced functions or functionality to the software, other than for medical
imaging international radiology applications.
1.12. "Prototype I" means a 50 millisecond working prototype unit of the
RTR-2000 TeraRecon System.
1.13. "Prototype II" means a 100 millisecond working prototype unit of the
RTR-2000 TeraRecon System.
1.14. "RTR-2000 TeraRecon System" means the first generation Real Time
Reconstruction ("RTR") imaging processing hardware and software to be developed
and created pursuant to this Agreement and to be used in conjunction with newly
manufactured or previously installed Imatron Ultrafast CT scanners only for
medical scanning applications and modifications and improvements to such image
processing software and hardware, including Imaging Enhancements and Hardware
Updates but excluding Non-Imaging Enhancements and Hardware Upgrades thereto.
1.15. "Specifications" means the technical and operational specifications
and system characteristics for the RTR-2000 TeraRecon System as set forth in the
Development Program attached to this Agreement as Appendix A.
1.16. "Technology" means any or all of the TeraRecon Technology, the
Imatron Technology or both.
1.17. "TeraRecon Systems" means image reconstruction hardware and software
developed by TeraRecon, including, without limitation, the RTR-2000 TeraRecon
System and all modifications and enhancements thereto.
1.18. "TeraRecon Technology" means the property technology of TeraRecon,
improvements or modifications to such technology, and all Intellectual Property
Rights included therein, included in and underlying the TeraRecon Systems, as
identified on Appendix C.
1.19. "Warrant" means a warrant to purchase Common Stock of Imatron in
substantially the form attached hereto as Appendix D.
2. DEVELOPMENT EFFORTS.
2.1. Collaboration. TeraRecon and Imatron hereby agree to undertake the
Development Program. Each party shall have the obligations set forth herein and
in Appendix A.
2.2. Development Obligations of the Parties.
2.2.1. Each party agrees, in cooperation with the other, to use
commercially reasonable efforts to realize the objectives of the Development
Program and to achieve the milestones on a timely basis, including, without
limitation, supplying the necessary personnel, facilities and materials
necessary to carry out the Development Program.
2.2.2. Imatron will: (a) make available to TeraRecon the Imatron Technology
as required by TeraRecon to perform its obligations under the Development
Program; and (b) provide to TeraRecon, as soon as reasonably available, copies
of the tangible aspects of such Imatron Technology including, without
limitation, applicable specifications and other engineering documents.
2.2.3. During the course of the Development Program, in the event that
either party reasonably believes modifications to the Development Program are
necessary to carry out the intent of this Agreement, the Development Program
shall be modified with the written consent of the other party, which consent
shall not be unreasonably withheld. The parties will then mutually agree upon
such changes in good faith. The parties shall cause Appendix A to be amended in
the event of any such modifications to reflect the changes to the Development
Program. An amended Appendix A shall supersede all prior Appendix A and become a
part of this Agreement.
2.2.4. No compensation will be due Imatron for its performance of its
obligations under this Agreement, and Imatron shall bear all of its own costs
and expenses associated with such performance: provided, however, that so long
as Imatron provides TeraRecon with certain space at Imatron's facility,
TeraRecon may be billed for telephone and fax expenses.
2.2.5. The parties agree that they shall have their personnel meet as
frequently as needed to determine scheduling and pertinent technical issues with
respect to the Development Program. Such meetings shall be held at such
locations as the parties shall jointly determine. Each party shall appoint a
qualified person to act as project manager. The project managers will act as
each party's representative and principal contact person regarding all matters
related to this Agreement.
2.2.6. Imatron shall provide TeraRecon with improved and updated
reconstruction algorithms and the parties further agree to otherwise cooperate
with one another to improve the image quality and performance of the RTR-2000
TeraRecon System.
3. ACCEPTANCE CRITERIA AND PERFORMANCE SPECIFICATIONS.
3.1. Acceptance Criteria. Each Prototype I and Prototype II (each a
"Prototype" or collectively the "Prototypes") shall be subject to acceptance
testing by Imatron to verify that each Prototype conforms to the Specifications
mutually agreed upon by Imatron and TeraRecon for said Prototype as set forth in
the Development Program and modified from time to time in accordance with
Section 2.2.3.
3.2. Acceptance Testing. Acceptance testing for the Prototype I and the
Prototype II shall commence when TeraRecon notifies Imatron in writing that such
prototype conforms to the Specifications, and is ready for acceptance testing by
Imatron (the "Completion Notice"). Within ten (10) days after receipt of the
Completion Notice, Imatron will perform acceptance tests at Imatron's South San
Francisco facility to determine whether such Prototype exhibits Errors. If a
Prototype conforms to the Specifications, Imatron will accept such Prototype by
sending written notice to TeraRecon. Imatron will be deemed to have
unconditionally accepted such Prototype if Imatron does not provide, within
thirty (30) days after receipt of the Completion Notice (the "Acceptance
Period"), written acceptance in accordance with this Section 3.2 or written
rejection in accordance with Section 3.2.1 below. For the purposes of this
Agreement, acceptance by written notice or by failing to provide written
acceptance or written rejection shall be deemed "Acceptance."
3.2.1. Retesting. If Imatron determines that the Prototype I or Prototype
II exhibits Errors on the basis of the acceptance testing, Imatron shall
promptly notify TeraRecon in writing ("Notice of Errors") and shall specify with
as much detail as possible the Errors exhibited by such Prototype. If TeraRecon
receives a Notice of Errors, TeraRecon and Imatron shall first cooperate in
seeking a way to correct the Errors which does not require a redesign of the
Prototype I or Prototype II, as applicable. Imatron will submit to TeraRecon
such data as TeraRecon may reasonably request in order to verify, diagnose and
correct an Error. If no such correction is possible in TeraRecon's reasonable
judgment, TeraRecon and Imatron shall agree in good faith on what design changes
are necessary to correct the Errors and then modify the Development Program and
amend Appendix A accordingly. TeraRecon shall then use reasonable commercial
efforts to correct the Errors at TeraRecon's sole cost and expense on a mutually
agreed upon schedule. Upon completion of the corrective action by TeraRecon, the
Acceptance Test will be repeated until such Prototype no longer exhibits Errors.
If correcting of such Errors is not feasible, as determined in TeraRecon's
reasonable commercial judgment, Imatron or TeraRecon may terminate this
Agreement in accordance with Section 14, which such termination shall be
Imatron's sole and exclusive remedy for TeraRecon's failure to remedy such
Error.
4. WARRANT PAYMENTS TO TERARECON.
4.1. Within ten (10) days of Acceptance by Imatron of the first Prototype
I, Imatron shall, for no additional charge, issue a Warrant to TeraRecon for the
purchase of 1,000,000 shares of Common Stock of Imatron (as adjusted for any
stock splits, dividends, recapitalizations or the like) with a four-year term at
an exercise price determined in accordance with Section 4.5 below.
4.2. Within ten (10) days of Acceptance by Imatron of three (3) additional
Prototype I units, TeraRecon shall purchase a Warrant of the purchase of
2,000,000 shares of Common Stock of Imatron (as adjusted for any stock splits,
dividends, recapitalizations or the like) with a four-year term at an exercise
price determined in accordance with Section 4.5 below for an aggregate purchase
price of $1,000,000.
4.3. Within ten (10) days of Acceptance by Imatron of the first Prototype
II unit, Imatron shall, for no additional charge, issue a Warrant to TeraRecon
for the purchase of 1,000,000 shares of Common Stock of Imatron (as adjusted for
any stock splits, dividends, recapitalizations or the like) with a four-year
term at an exercise price determined in accordance with Section 4.5 below.
4.4. Within ten (10) days of Acceptance by Imatron of six (6) additional
Prototype II units, TeraRecon shall purchase a Warrant for the purchase of
2,000,000 shares of Common Stock of Imatron (as adjusted for any stock splits,
dividends, recapitalizations or the like) of Imatron with a four-year term at an
exercise price determined in accordance with Section 4.5 below for an aggregate
purchase price of $1,000,000.
4.5. The exercise price for the Warrants issued pursuant to Sections 4.1
through 4.4 above shall be $4.50 per share; provided that if the Fair Market
Value of the Common Stock of Imatron is less than $2.00 per share than the
exercise price shall be equal to 180% of such Fair Market Value; provided
further, that the exercise price shall not be less than $1.50 per share in any
case.
4.6. Investment Representations.
(a) Risk. TeraRecon is aware that an investment in Imatron is highly
speculative and that there can be no assurance as to what, if any, return that
there may be on TeraRecon's investment in the Warrants and the share of Imatron
common stock to be issued upon exercise of the Warrants (the "Shares"). The
Warrants and the Shares are collectively referred to herein as the "Securities."
TeraRecon is aware of Imatron's business affairs and financial condition and has
acquired sufficient information about Imatron to be able to evaluate the risks
and merits of the proposed investment and to reach an informed and knowledgeable
decision to acquire the Securities.
(b) Experience. TeraRecon is capable of evaluating the merits and risks of
its investment in Imatron and has the capacity to protect its own interests.
TeraRecon also represents it has not been organized for the purpose of acquiring
the Securities offered hereby.
(c) Principal Place of Business. TeraRecon's principal place
of business is located at the address set forth below.
(d) Investment. TeraRecon is acquiring the Securities for investment for
its own account, not as a nominee or agent, and not with the view to, or for
public resale in connection with, any distribution thereof other than pursuant
to a registration as contemplated hereby. TeraRecon understands that the
Warrants and the Shares have not been registered under the Securities Act by
reason of a specific exemption from the registration provisions of the
Securities Act, the availability of which depends upon, among other things, the
bona fide nature of the investment intent and the accuracy of such purchaser's
representations as expressed herein.
(e) Rule 144. TeraRecon acknowledges that the Securities are characterized
as "restricted securities" under the federal securities laws and must be held
indefinitely unless subsequently registered under the Securities Act or unless
an exemption from such registration is available. TeraRecon is aware of the
provisions of Rule 144 promulgated under the Securities Act which permits
limited public resale of shares purchased in a private placement subject to the
satisfaction of certain conditions, including, among other things, the existence
of a public market for the shares, the availability of certain current public
information about the issuer, the resale occurring not less than two years after
a party has purchased and paid for the security to be sold, the sale being
effected through a "broker's transaction" or in transactions directly with a
"market maker" and the number of shares being sold during any three-month period
not exceeding specified limitations.
(f) Access to Data. TeraRecon has had an opportunity to discuss Imatron's
businesses, management and financial affairs with its management and the
opportunity to review Imatron's facilities and financial data. TeraRecon has
also had an opportunity to ask questions of officers of Imatron, which questions
were answered to its, his or her satisfaction.
4.7. Warrant Purchase Agreement. In connection with the offer and issuance
of any of the Securities, the parties agree to execute and deliver to each other
a Warrant Purchase Agreement in the form of Appendix E hereto
5. RESTRICTIONS ON USE.
5.1. Prototype I and Prototype II Use. The use of the Prototype I and
Prototype II shall be limited to product development, promotional purposes,
training, engineering "Alpha" testing and clinical "Beta" testing and expressly
not for commercial production, distribution or medical treatment of any person
without the prior written consent of TeraRecon. The Prototype I and Prototype II
are intended for human use in their "Alpha" and "Beta" testing applications in
clinical settings; provided, however, that Imatron will defend, indemnify and
hold harmless TeraRecon from and against any losses, damages, expenses or other
costs (including, without limitation, reasonable attorney's fees) arising out of
or resulting from any claims in connection with any human use, treatment,
observation and/or diagnosis.
5.2. Trademark Display. TeraRecon will provide to Imatron copies of its
logos and/or trademarks (the "Marks") for the purposes of including the Marks in
any display or demonstration of the RTR-2000 TeraRecon System by Imatron.
Imatron will use the Marks during any such display or demonstration in
conformance with such written instructions as TeraRecon may provide to Imatron
from time to time.
5.3. No Unauthorized Warranties. Imatron will not make or extend on behalf
of TeraRecon any written or oral warranty with respect to any RTR-2000 TeraRecon
System without the express prior written consent of TeraRecon. Imatron will not
advise, perform or demonstrate any use or application of any RTR-2000 TeraRecon
System that is not specifically approved in writing by TeraRecon. Imatron will
not impair the integrity of the RTR-2000 TeraRecon System while it is in
Imatron's custody.
5.4. Compliance with Laws. Imatron represents and warrants that it is
familiar and will comply in all respects with applicable laws, ordinances,
regulations and other governmental requirements concerning the marketing, sale,
demonstration, use and distribution of the Imatron Ultrafast CT Scanner,
including, without limitation, regulations of the Food and Drug Administration
("FDA"). TeraRecon shall be responsible for obtaining applicable FDA approval,
IEC601 approval, and CE Mark and ISO 9001 approval in accordance with applicable
European regulations for the RTR-2000 TeraRecon System; provided that Imatron
will fully cooperate with and assist TeraRecon in obtaining all such approvals.
Notwithstanding the foregoing, TeraRecon shall not be required to obtain any
such approvals for the Prototype I or Prototype II.
5.5. Indemnification. Imatron will defend, indemnify and hold harmless
TeraRecon from and against any losses, damages, expenses or other costs
(including, without limitation, reasonable attorney's fees) arising out of or
resulting from any breach or alleged breach of this Section 5.
6. MANUFACTURE AND SALE AGREEMENT.
Upon successful completion of the Development Program, Imatron and
TeraRecon shall in good faith enter into a manufacture and sale agreement which
shall include, without limitation, the following:
6.1. TeraRecon shall manufacture and sell the RTR-2000 TeraRecon Systems to
Imatron on an OEM basis for distribution solely in connection with the Imatron
Ultrafast CT Scanner for medical use;
6.2. Imatron shall have an exclusive right to sell or lease the RTR-2000
TeraRecon Systems to existing owners of the Imatron Ultrafast CT Scanner and to
purchasers of the Imatron Ultrafast CT Scanner in connection with such purchase;
provided, however, that in the event Imatron ceases to use its best efforts
(including customary print and promotional materials, product demonstrations,
sales people and trade show promotions) to sell or lease the TRT-2000 TeraRecon
Systems, as determined in good faith by both Imatron and TeraRecon, then
Imatron's exclusive sales right as set forth in this Section 6.2 shall
terminate;
6.3. TeraRecon shall retain the right to sell, lease or license the
TeraRecon Systems to other medical imaging systems customers; provided, however,
that such TeraRecon Systems shall not include any Imatron Technology;
6.4. The purchase price for the RTR-2000 TeraRecon System shall be $40,000
through December 31, 1998;
6.5. TeraRecon shall make the RTR-2000 TeraRecon System available to
Imatron for the five-year period commencing on the Effective Date; provided that
if TeraRecon terminates production of the RTR-2000 TeraRecon System before such
time, TeraRecon shall provide Imatron with a replacement TeraRecon System which
meets the Specification and performs at least the same set of functions as the
RTR-2000 TeraRecon System performs;
6.6. Such additional terms and conditions as are necessary and appropriate,
including, without limitation, customary provisions relating to limited
warranties and limitation of liability between the parties and with respect to
customers.
7. INTENTIONALLY DELETED.
8. ROYALTY PAYMENTS TO IMATRON.
8.1. TeraRecon shall make royalty payments to Imatron equal to 3% of the
Net Sales (the "Royalty Payments"), provided, however, that TeraRecon shall not
be required to make such Royalty Payments:
(a) on the sale, lease or license of RTR-2000 TeraRecon Systems occurring
after the fourth anniversary of the Effective Date; or
(b) in the event that Imatron fails to perform in any material way under
the terms of this Agreement or any other agreement between the parties hereto,
including the agreements contemplated hereby; or
(c) relating to any fiscal year in which Imatron does not purchase the
greater of five (5) RTR-2000 TeraRecon Systems and that number of RTR-2000
TeraRecon Systems equal to at least 30% of the number of Imatron Ultrafast CT
Scanners sold, leased or licensed in such fiscal year.
8.2. Royalty Payments shall be made as soon as practicable after the end of
each fiscal year of TeraRecon, and in any event within sixty (60) days
thereafter.
9. OWNERSHIP OF TECHNOLOGY.
9.1. TeraRecon Technology; Imatron Technology. The parties agree that
TeraRecon shall retain all right, title and interest in and to the TeraRecon
Technology, and all Intellectual Property Rights therein, and that Imatron shall
retain all right, title and interest in and to the Imatron Technology, and all
Intellectual Property Rights therein.
9.2. Newly Created Technology. The parties agree that TeraRecon shall own
all right, title and interest in and to any new technology developed or created
pursuant to, or otherwise arising out of the Development Program (including,
without limitation, the TeraRecon Systems), any improvements and modifications
to such new technology, and all Intellectual Property Rights therein. To the
extent that Imatron may be deemed to have assisted TeraRecon in or otherwise to
have contributed to the development or creation of such new technology, Imatron
hereby assigns to TeraRecon all right, title and interest Imatron may have in
and to such new technology, including all Intellectual Property Rights therein.
10. NO GRANT OF LICENSE.
Nothing in this Agreement or the Development Program shall imply that any
license to the Imatron Technology shall have been transferred from Imatron to
TeraRecon or that any license to the TeraRecon Technology shall have been
transferred from TeraRecon to Imatron. TeraRecon represents that it will not
include Imatron Technology in the TeraRecon Systems manufactured for other
medical imaging systems customers; provided that Imatron agrees and acknowledges
that nothing in this Agreement shall be deemed or construed to prevent TeraRecon
from developing, manufacturing and selling TeraRecon Systems to other medical
imaging systems customers. In particular, Imatron agrees that, notwithstanding
anything to the contrary in this Section 10, TeraRecon shall be free to use or
disclose to any third party any generalized ideas, concepts, know-how, methods,
techniques or skills in possession of TeraRecon prior to the Development Program
or gained or learned by TeraRecon during the course of the Development Program,
so long as such use or disclosure does not infringe on any patent, copyright,
trade secret or trademark of Imatron or include any Confidential Information of
Imatron as defined in Section 1.1. TeraRecon agrees and acknowledges that
nothing in this Agreement shall be deemed or construed to prevent Imatron from
developing, manufacturing and selling image reconstruction systems; provided,
however, that such image reconstruction systems shall not include any TeraRecon
Technology.
11. WARRANTY DISCLAIMER.
IMATRON AGREES AND ACKNOWLEDGES THAT THE PROTOTYPE I AND PROTOTYPE II ARE
PROVIDED AS-IS, AND THAT TERARECON MAKES NO REPRESENTATION OR WARRANTY OF ANY
KIND WITH REGARD TO ANY PRODUCT FURNISHED UNDER THIS AGREEMENT. TERARECON HEREBY
EXPRESSLY DISCLAIMS ALL WARRANTIES AND OBLIGATIONS OF TERARECON, EXPRESS OR
IMPLIED, ARISING BY LAW OR OTHERWISE, WITH RESPECT TO THE PROTOTYPE I, PROTOTYPE
II OR ANY OTHER PRODUCTS DELIVERED BY OR ON BEHALF OF TERARECON UNDER THIS
AGREEMENT (INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE).
12.INTELLECTUAL PROPERTY INDEMNITY.
12.1. TeraRecon and its affiliates own all right, title and interest in the
TeraRecon Technology. TeraRecon has the power to cause and will cause such
affiliates to transfer to TeraRecon all technology necessary for TeraRecon to
perform under this Agreement. TeraRecon represents and warrants that the use of
the TeraRecon Technology in the development, creating and manufacture of the
Prototype I and Prototype II does not infringe any copyright, trademark or trade
secret rights of any third party.
12.2. Imatron owns all right, title and interest in the Imatron Technology
necessary for Imatron to perform under this Agreement. Imatron represents and
warrants that the use of the Imatron Technology in the development, creation and
manufacture of the Prototype I and Prototype II does not infringe any copyright,
trademark or trade secret rights of any third party.
12.3. Each party will defend, indemnify and hold harmless the other party
from and against any breach or alleged breach of Section 12.1 or 12.2, as
applicable, and pay any costs, damages, liabilities or expense (including
reasonable attorneys' fees) incurred by the other arising out of or relating to
such action, provided the party seeking indemnification ("Indemnified Party" (i)
notifies the indemnifying party ("Indemnifying Party") promptly in writing of
any such action; (ii) gives the indemnifying party sole control of the defense
and any negotiations for settlement or compromise of such action; (iii)
cooperates with the Indemnifying Party and provides such assistance as the
Indemnifying Party may reasonably request in connection with the defense or
settlement of the claim; (iv) does not settle the claim without the Indemnifying
Party's written consent, which consent will not be unreasonably withheld; and
(v) complies with any settlement or court order made in connection with the
claim. Should the Indemnifying Party's Technology become, or in the Indemnifying
Party's opinion be likely to become, the subject of such an action, the
Indemnified Party shall permit the Indemnifying Party, at the Indemnifying
Party's option and sole expense, either (A) to procure for the Indemnified Party
the right to continue using the Indemnifying Party's Technology or (B) replace
or modify the same to become noninfringing if such replacement or modification
does not materially affect the performance of the Product. The Indemnified Party
agrees to provide reasonable assistance to the Indemnifying Party to procure
such rights or replace or modify the Indemnifying Party's Technology at the
Indemnifying Party's expense. However, the Indemnifying Party shall have no
liability to the Indemnified Party under this Section 12 for any such action
based upon (A) any modification of the Indemnifying party's Technology or (B)
the combination of the Indemnifying Party's Technology with other items by the
Indemnified Party other than as contemplated by this Agreement if such action
would have been avoided by the absence of such combination or modification. This
Section 12.3 sets forth each party's exclusive remedy and entire liability for a
breach or alleged breach of Section 12.1 or 12.2, as applicable.
13. Non-Disclosure.
13.1. Scope of Use. Each party will use the Confidential Information solely
to accomplish the purposes of this Agreement and will not disclose the
Confidential Information to any person except its employees or consultants to
whom it is necessary to disclose the Confidential Information for such purposes.
Each party agrees that the Confidential Information will be disclosed or made
available only to those of its employees or consultants who have agreed to
receive it under terms at least as restrictive as those specified in this
Agreement. Each party agrees not to copy, alter, modify, disassemble, reverse
engineer or otherwise reproduce any of the Confidential Information, except as
required to accomplish the intent of this Agreement, unless permitted in writing
by the Disclosing Party. Each party will use its bets efforts to maintain the
confidentiality of the Confidential Information, but not less than the measure
it uses for its own confidential information of similar type. Each party will
immediately notify the other of any unauthorized use or disclosure of the
Confidential Information and will assist the other in remedying any such
unauthorized use or disclosure.
13.2. Permitted Disclosure. Notwithstanding Section 13.1, disclosure of
Confidential Information shall not be precluded if such disclosure: is in
response to a valid order of a court or other governmental body of the United
States or any political subdivision thereof; provided, however, that the
responding party shall first have given notice to the other party hereto and
shall have made a reasonable effort to obtain a protective order requiring the
that Confidential Information so disclosed be used only for the purposes for
which the order was issued; is otherwise required by law; or is otherwise
necessary to establish rights or enforce obligations under this Agreement, but
only to the extent that any such disclosure is necessary.
13.3. No Solicitation of Employees. During the two-year period commencing
with the Effective Date, neither TeraRecon nor Imatron, nor any affiliates of
TeraRecon or Imatron, will solicit or seek to employee any employee of the other
party, or any affiliate of such other party.
14. TERM AND TERMINATION.
14.1. Term. The term of this Agreement will begin on the Effective Date and
will continue until the final milestone is completed and accepted and TeraRecon
receives the Warrants pursuant to Section 4, unless earlier terminated
hereunder.
14.2. Termination. Notwithstanding anything herein to the contrary, either
party will have the right, in addition and without prejudice to any other rights
or remedies, to terminate this Agreement if:
14.2.1. Both parties agree in writing to so terminate this Agreement; or
14.2.2. The other party commits a material breach of the terms hereof that
has not been remedied within ninety (90) days of the receipt by the party in
default of notice specifying the breach and requiring its remedy; or
14.2.3. TeraRecon determines in its reasonable commercial judgment that it
is not feasible to correct errors after completing the retesting procedure in
Section 3.2.1.
14.2.4. TeraRecon has not delivered the Prototypes in accordance with the
Milestone Schedule set forth in the Development Program, as modified from
time-to-time by Sections 2.2.3 and 3.2.1.
14.3. Accrued Rights. Termination or expiration of this Agreement will not
affect any other rights of the parties which may have accrued up to the date of
such termination or expiration and, in addition, no party will be relieved of
any obligation for any sums due to the other party.
14.4. Survival. The following Sections will survive any expiration or
termination of this Agreement: 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 17 and 18.
15. LIMITATION OF LIABILITY.
15.1. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY
THIRD PARTY FOR ANY CONSEQUENTIAL, EXEMPLARY, SPECIAL, INDIRECT OR INCIDENTAL
DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, DATA, SAVING OR REVENUES,
ARISING OUT OF OR RELATED TO THIS AGREEMENT, WHETHER UNDER TORT, CONTRACT OR
OTHER THEORIES OF LIABILITY (INCLUDING STRICT LIABILITY), EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
15.2. IN NO CASE WILL TERARECON'S LIABILITY UNDER THE TERMS OF THE
AGREEMENT EXCEED THE AMOUNTS ACTUALLY PAID TO TERARECON HEREUNDER. FOR PURPOSES
OF THIS SECTION, NO VALUE WILL BE ATTRIBUTED TO WARRANTS WITH A SHARE PRICE
GREATER THAN THE CURRENT FAIR MARKET VALUE OF THE COMMON STOCK ON THE EFFECTIVE
DATE.
16. ASSIGNMENT.
No party may assign its rights or obligations under this Agreement to any
third party without the prior written consent of the other party, except that a
party may assign such rights and obligations to an entity which purchases or
otherwise acquires all or substantially all of the assets of such party.
17. GENERAL PROVISIONS.
17.1. Force Majeure. No party hereto will be liable for default of any
obligation hereunder other than the payment of money if such default results
from force majeure, including, without limitation, governmental acts or
directives; strikes or shortage of supplies; acts of God; war; insurrection,
riot or civil commotion; fires, explosions, flooding, earthquakes or water
damage; or embargoes; or any other events whether of the kind herein enumerated
or otherwise, that are not within the reasonable control of the party affected.
In such event, and as a condition to excuse of performance by reason of this
Section 17.1, the affected party will promptly give notice of the circumstances
responsible for such party's nonperformance to the other parties, and the
affected party will act in good faith and use commercially reasonable efforts to
remedy or minimize the effects of such circumstances.
17.2. No Agency. The parties to this Agreement are independent contractors.
Nothing in this Agreement shall be construed as creating any agency,
partnership, joint venture or any other form of joint enterprise between the
parties.
17.3. Notices. Any notice required or permitted under this Agreement will
be given in writing and will be deemed effectively given upon personal delivery
to the party to be notified by hand, professional courier service or facsimile,
one day after deposit with Federal Express or other overnight delivery service,
or two days after deposit with the United States Post Office, by registered or
certified mail, postage prepaid and addressed to the party to be notified at the
address as set forth below, or at such other address as such party may designate
by five days' advance written notice to the other party.
17.4. Application of California Law. This Agreement will be governed
exclusively by its terms and by the laws of the State of California, without
regard to conflict of laws principles.
17.5. Amendments. An amendment to this Agreement will be effective only by
a writing executed by the parties to this Agreement.
17.6. Headings. The headings in this Agreement are inserted for convenience
only and are in no way intended to describe, interpret, define, or limit the
scope, extent or intent of this Agreement or any provisions hereof.
17.7. Waivers. The failure of any party to seek redress for violation of
any term, covenant or condition of this Agreement will not prevent a subsequent
act, that would have originally constituted a violation, from having the effect
of an original violation.
17.8. Rights and Remedies Cumulative. The rights and remedies provided by
this Agreement are cumulative, and the use of any one right or remedy by any
party will not preclude or waive the right to use any or all other remedies.
Such rights and remedies are given in addition to any other rights the parties
may have by law, statute, ordinance or otherwise.
17.9. Entire Agreement. This Agreement, together with any attachments and
exhibits hereto, constitute the entire agreement of the parties with respect to
their subject matter, and supersede and replace any prior or contemporaneous
understandings or agreements, whether oral or written, between the parties
including, without limitation, the Agreement in Principle, dated March 7, 1997,
between the parties hereto and the Non-Disclosure Agreement, dated March 10,
1997, between the parties hereto.
17.10. Severability. If any provision of this Agreement or the application
thereof to any person or circumstance will be invalid, illegal or unenforceable
to any extent, the remainder of this Agreement and application thereof will not
be affected and will be enforceable to the fullest extent permitted by law.
17.11. Heirs, Successors and Assigns. Each and all of the covenants, terms,
provisions and agreements herein contained will be binding upon and inure to the
benefit of the parties hereto and, to the extent permitted by this Agreement,
their respective heirs, legal representatives, successors and assigns.
17.12. Counterparts. This Agreement may be executed in counterparts, each
of which will be deemed an original but all of which will constitute one and the
same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
Effective Date.
TERARECON INC.
By:
-----------------------------------------------
Name:
----------------------------------------------
Title:
---------------------------------------------
Address:
---------------------------------------------
---------------------------------------------
---------------------------------------------
Attn:
---------------------------------------------
IMATRON INC.
By:
----------------------------------------------
Name:
---------------------------------------------
Title:
---------------------------------------------
Address:
---------------------------------------------
---------------------------------------------
---------------------------------------------
Attn:
---------------------------------------------
<PAGE>
APPENDIX A
DEVELOPMENT PROGRAM
A. RTR-2000 TERARECON SYSTEMS
The Prototype I and Prototype II will be developed on a time frame
consistent with the Milestone Schedule below.
B. MILESTONE SCHEDULE
1. Delivery of the first Prototype I shall be made no later than August
31, 1997.
2. Delivery of three (3) additional Prototype i units shall be made
within thirty (30) days of Acceptance of the first Prototype I.
3. Delivery of the first Prototype II shall be made within sixty (60)
days of Acceptance of the first Prototype I.
4. Delivery of six (6) additional Prototype II units shall be made within
thirty (30) days of Acceptance of the first Prototype II.
5. Upgrade of four (4) Prototype I units to Prototype II units shall be
made within thirty (30) days of delivery of six (6) Prototype II units
pursuant to provision B(4) above.
C. SPECIFICATIONS
Prototype I. 50 Millisecond mode, all pictures are 256 by 256
1. Cine Fluoro-mode 17.2 frames per second real-time reconstruction mode.
Image quality should be comparable to Imatron 50 millisecond pictures.
2. Averaged Fluoro-mode Two to six, "n", data sets would be averaged and
then reconstructed. This would run at 17.2/n frames per second. The
usual speed would probably be 17.2/3 = 5.7, advertised as 6. With the
new detector this might produce 5 rows of holes, high and low
contrast.
Prototype II. 100 millisecond mode, 256 by 256 zoom or 512 by 512
1. Triggered Average Mode.
A trigger takes n sweeps. The data from these is averaged and then
the picture is reconstructed. The time to display the image after
scanning stops is: 360 milliseconds.
2. Averaged Fluoro-mode. Three or more data sets are averaged and then
the average is displayed.
Themaximum running rate is3 frames per second.The image quality of the
Prototype II should be comparable to the C-150 pictures of the same
data. In the event of a disagreement about image quality, a panel of
three independent interventional radiologists will evaluate such image
quality. The panel shall be comprised of one independent radiologist
appointed by each of Imatron and Tera Recon and a third independent
radiologists chosen by mutual agreement of the first two radiologists.
<PAGE>
APPENDIX B
IMATRON TECHNOLOGY
(1) Method to make pin interpolation for Imatron scanner data
(2) Details of scatter correction for Imatron scanner data
(3) Beam hardening correction
(4) Function to find coefficients to optimize convolution kernel
specifically designed for Imatron scanner
(5) General advice on mathematical computation method
<PAGE>
APPENDIX C
TERARECON TECHNOLOGY
(1) Know-how of implementing computerized data correction
(2) Know-how of implementing reconstruction of the images from the
projected data sets using HISC processor (Imagine 1)
(3) Know-how of implementing device driver for RTR-2000 TeraRecon Systems
(4) Know-how of implementing the visualization function for reconstructed
images using HISC processor (Imagine 1)
(5) The source does of the programs developed for RTR-2000 TeraRecon
Systems
(6) Programming method using HISC processor
(7) Know-how of developing the custom boards using HISC processors
(8) Know-how of high-speed data transfer board system for RTR-2000
TeraRecon Systems
(9) Know-how o high-speed data acquisition board systems for Imatron
system in connection with the RTR-2000 TeraRecon Systems
(10) Know-how of modifying Imatron's data capture board for the use of
high-speed data acquisition board system in connection with the
RTR-2000 TeraRecon Systems.
<PAGE>
APPENDIX D
WARRANT
<PAGE>
APPENDIX E
WARRANT PURCHASE AGREEMENT
EXHIBIT 7.2
Contact:
S. Lewis Meyer, President/CEO Jeffrey Lloyd/Jody Martin
Gary Brooks, VP Finance/CFO Sitrick And Company
Lisa Kimberlin, Investor Relations (310) 788-2850
(415) 583-9964
Tim Frandsen, TeraRecon
(415) 816-4511
For Immediate Release
IMATRON AND TERARECON SIGN DEVELOPMENT AGREEMENT
Positions Imatron to Enter Interventional Radiology Market
So. San Francisco, Calif., July 30, 1997 -- Imatron Inc. (Nasdaq: IMAT)
today announced that it has entered into a development agreement with TeraRecon
Inc., which will expand Imatron's Ultrafast CT(R) current applications to
include new, 3-D, CT fluorography, or real-time viewing of CT images. The
agreement provides Imatron with proprietary, real-time, image reconstruction
systems for CT (computerized tomography) applications in the interventional
radiology market. Called the RTR-2000, this system will reconstruct data at a
rate of seventeen complete images per second.
Upon completion of development and when delivered, the RTR-2000 will be
exclusive to Imatron's Ultrafast CT scanner. This new technology will enable
Imatron to be an immediate market contender in the areas of interventional
radiology and real-time, image guided microsurgery, by having scan and
reconstruction times significantly faster than existing technologies.
In consideration for the successful development and delivery of
specifically mandated RTR-2000 systems, Imatron has agreed to issue to TeraRecon
an aggregate of 6 million warrants to purchase Imatron's common stock at $4.50
per share. The warrants will be issued in installments based on TeraRecon
achieving certain milestones. In addition to delivering the systems, TeraRecon
has agreed to pay the Company an aggregate of $2 million for 4 million of the
warrants and to pay a royalty on certain image reconstruction systems sold to
third parties.
S. Lewis Meyer, President and CEO of Imatron, stated, "This agreement with
TeraRecon positions Imatron to enter medical imaging markets previously not
pursued by the Company, such as interventional radiology. A recent Frost &
Sullivan medical imaging market report characterized the interventional
radiology market as an opportunity for `soaring' future growth. Not only will
the technological superiority of the RTR-2000 establish our Ultrafast CT scanner
as a major participant in general CT imaging, but it will also strengthen our
exclusive, pioneering position in cardiac imaging and coronary artery scanning.
"Imatron scanners equipped with the new RTR-2000 will provide many
additional capabilities such as real-time monitoring of patient scans, real-time
viewing of the flow of contrast medium and real-time, image guided microsurgery,
in addition to real-time, CT guided, surgical biopsies and faster general
radiology exam times. We are very excited to be working with TeraRecon on these
unrivaled advances with Ultrafast CT, and are eager to launch the RTR-2000
implementation over the next few months," Mr. Meyer added.
The first prototype RTR-2000 systems are expected to be delivered to
Imatron in late September, with production quantity deliveries scheduled to
begin by November 1, 1997. The Company is already in negotiations to place these
proprietary systems at various sites. Each system will be available as an
upgrade kit for Imatron Ultrafast CT C-100 and C-150 customers.
According to Motoaki Saito, M.D., President and CEO of TeraRecon, "We are
pleased to be working with Imatron on this significant enhancement to electron
beam tomography technology. Our relationship with Imatron will certainly benefit
TeraRecon, a newly formed, high technology company, by aligning our innovation
with Imatron's superb engineering and physics, and furthering our goals in
real-time, reconstruction technology."
TeraRecon Inc., a privately-held company based in South San Francisco,
produces high speed, image processing devices and software, specifically
designed for CT, MRI and Ultrasound. The Company bases its real-time, image
reconstruction systems on an array of unique, high speed, HISC microprocessors.
These microprocessors reconstruct the data, which is transferred from the
Ultrafast CT scanner through a fiber optic cable. TeraRecon holds an exclusive
license to use HISC microprocessors in the field of medical imaging
reconstruction. HISC technology is the advanced form of the newly introduced
VLIW chip architecture. The sixteen HISC microprocessor chips used in
TeraRecon's RTR-2000 perform 115.2 billion operations per second - significantly
faster than VLIW microprocessor chips.
Imatron Inc. is primarily engaged in designing, manufacturing and marketing
high performance computed tomography (CT) scanners based on the Company's
proprietary scanning electron beam technology. Ultrafast CT(R) is a registered
trademark of Imatron. Imatron's Ultrafast CT scanner is now in use at major
medical centers around the world, including The Mayo Clinic, University of Iowa,
National Institutes of Health, UCLA, Stanford University, University of
Illinois, The Royal Brompton Hospital in London, Tokyo University Hospital,
Beijing Hospital, as well as many other major hospital centers. Imatron's
HeartScan Imaging Inc. subsidiary provides Coronary Artery Disease Risk
Assessment diagnostic services in a nationwide network of Company-owned clinics.
Except for the historical information contained herein, the matters
discussed in this news release may contain forward-looking statements that are
based on current expectations and estimates about the industry in which Imatron
operates, the estimated impact of certain technological advances, the estimated
impact of published research studies on scanner sales and procedures, as well as
management's beliefs and assumptions. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "estimates," variations of such words and
similar expressions are intended to identify such forward-looking statements. It
is important to note that the Company's actual results could differ materially
from those projected in such forward-looking statements. The factors that could
cause actual results to differ materially include, among others: failed clinical
demonstration of certain asserted technological advantages and diagnostic
capabilities; reliance on product distributors; competition in the diagnostic
imaging market; failure to improve product reliability or introduce new product
models and enhancements; delays in production and difficulty in obtaining
components and sub-assemblies from limited sources of supply; inability to meet
cash-on-delivery or prepayment terms from vendors; determinations by regulatory
and administrative government authorities; patent expiration and denial of
patent applications; the high cost of the scanner as compared to commercially
available CT scanners; and the risk factors listed from time to time in the
Company's Securities and Exchange Commission reports, including their reports on
Form 10-K for their current fiscal year.
